Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial

Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Two screenshots show only minor UI/formatting differences with no changes to study details, eligibility criteria, or interventions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T01:22:19.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    35 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    3%
    Check dated 2025-10-05T09:59:47.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    Update to version from v3.0.2 to v3.1.0, indicating a new release; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T03:13:26.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The page version is updated from v3.0.1 to v3.0.2; the v3.0.1 reference was removed and the Back to Top link was deleted. No other substantive content changes are present.
    Difference
    0.2%
    Check dated 2025-09-13T17:16:14.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T14:52:14.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility names and locations, as well as additional drug information related to cancer treatment. Notably, the publication list has been expanded with a recent study on spartalizumab and its combination with chemotherapy.
    Difference
    11%
    Check dated 2025-08-30T11:45:19.000Z thumbnail image

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.